Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress

Poster to highlight data on safety, tolerability, pharmacokinetics, and effects on hepcidin and measures of iron metabolism of DISC-0974 from phase 1 study in healthy volunteers WATERTOWN, Mass., May 16, 2022 /PRNewswire/ — Disc Medicine, a biotechnology company dedicated to the…

Click here to view original post